Finance

Lists
IMNM:NASDAQ
Immunome Inc
$24.97
-4.40%
(-1.15) 1D
$24.90
-0.28% (-0.070)
Pre-market
Closed: Sep 10, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for IMNM...
Open
$25.69
High
$26.08
Low
$24.91
Mkt. cap
2.84B
Avg. vol.
1.07M
Volume
5.91K
52-wk high
$30.06
52-wk low
$8.93
EPS
-$2.51
Beta
2.13
Shares outstanding
113.58M
No. of employees
247
Open
$25.69
High
$26.08
Low
$24.91
Mkt. cap
2.84B
Avg. vol.
1.07M
Volume
5.91K
52-wk high
$30.06
52-wk low
$8.93
EPS
-$2.51
Beta
2.13
Shares outstanding
113.58M
No. of employees
247
News stories
From web sources and news partners
About Immunome Inc
CEO-
Employees247
Founded2006
HeadquartersBothell, Washington, United States
SectorBiotechnology
Analyst ratings
Based on 11 analysts giving stock ratings to IMNM in the past 3 months
Strong buy
Buy
11
Hold
0
Sell
0
12-month forecast
Based on 11 Wall Street analysts offering 12 month price targets for IMNM in the last 3 months.
Highest
Current $24.97
$40.00 (+60.19%)
Average
$37.00 (+48.18%)
Lowest
$33.00 (+32.16%)
Analyst
Recommendation
Action
Price target
Projected
Date
Andres Y. Maldonado
H.C. Wainwright
Buy
Maintained
$40.00
+60.2%
09/10/2026
Michael Schmidt
Guggenheim
Buy
Maintained
$35.00
+40.2%
08/12/2026
Unknown Analyst
Wedbush
Buy
Maintained
$35.00
+40.2%
08/12/2026
Cory Kasimov
Evercore ISI
Buy
Maintained
$40.00
+60.2%
08/12/2026
Adam Vogel
Craig-Hallum
Buy
Maintained
$36.00
+44.2%
08/12/2026
Supawat Thongthip
Truist Financial
Buy
Maintained
$38.00
+52.2%
08/12/2026
Biren Amin
Piper Sandler
Buy
Maintained
$33.00
+32.2%
08/12/2026
Charles Zhu
LifeSci Capital
Buy
Reiterated
$40.00
+60.2%
08/12/2026
Lukas Shumway
Barclays
Buy
Maintained
$36.00
+44.2%
08/11/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
-
-
08/11/2026
Brian Cheng
J.P. Morgan
Buy
Maintained
-
-
06/29/2026
Chad Messer
Lake Street
Buy
Maintained
$30.00
+20.1%
06/01/2026
Unknown Analyst
Barclays
Buy
Initiated
$36.00
+44.2%
05/28/2026
Andrew Berens
Leerink Partners
Buy
Maintained
$33.00
+32.2%
05/15/2026
Salveen Richter
Goldman Sachs
Buy
Maintained
$35.00
+40.2%
05/13/2026
Karina Rabayeva
Truist Financial
Buy
Maintained
-
-
03/05/2026
Sudan Loganathan
Stephens
Buy
Reiterated
$30.00
+20.1%
03/04/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
49.19M
50.77M
46.38M
59.88M
Cost of revenue
49.19M
50.77M
46.38M
59.88M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
10.94M
12.09M
12.95M
18.25M
Operating expense
10.94M
12.09M
12.95M
18.25M
Total operating expenses
60.14M
62.86M
59.33M
78.14M
Operating income
-60.14M
-62.86M
-59.33M
-78.14M
Other non operating income
-
-
-
-
EBT including unusual items
-57.46M
-69.90M
-53.84M
-73.13M
EBT excluding unusual items
-57.46M
-59.90M
-53.84M
-73.13M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-57.46M
-69.90M
-53.84M
-73.13M
Net profit margin
-
-
-
-
Earnings per share
-0.65
-0.76
-0.48
-0.65
Interest and investment income
2.68M
2.96M
5.49M
5.01M
Interest expense
-
-
-
-
Net interest expenses
2.68M
2.96M
5.49M
5.01M
Depreciation and amortization charges
-
-
-
-
EBITDA
-59.55M
-62.23M
-58.73M
-77.18M
Gain or loss from assets sale
-50.00K
55.00K
79.00K
-1.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google apps